Back to Search
Start Over
Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats
- Source :
- BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021), BMJ Open Diabetes Research & Care
- Publication Year :
- 2021
- Publisher :
- BMJ Publishing Group, 2021.
-
Abstract
- IntroductionSodium glucose cotransporter-2 (SGLT2) inhibitors are widely used for diabetes treatment. Although SGLT2 inhibitors have been clinically observed to increase food intake, roles or even the presence of SGLT2 in the central nervous system (CNS) has not been established. We aimed to elucidate potential functions of SGLT2 in the CNS, and the effects of CNS-targeted SGLT2 inhibitors on food intake.Research design and methodsWe administered three kinds of SGLT2 inhibitors, tofogliflozin, dapagliflozin, and empagliflozin, into the lateral ventricle (LV) in rats and evaluated their effects on food intake. We also evaluated the effects of tofogliflozin administration in the third (3V) and fourth ventricle (4V). Intraperitoneal administration of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist known to suppress food intake, was combined with central tofogliflozin to elucidate whether GLP-1 signaling antagonizes the effect of central SGLT2 inhibitors on food intake. To elucidate potential molecular mechanisms mediating changes in feeding, hypothalamic areas associated with food intake regulation were harvested and analyzed after intracerebroventricular administration (ICV) of tofogliflozin.ResultsBolus ICV injection of tofogliflozin induced a robust increase in food intake starting at 1.5 hours postinjection, and lasting for 5 days. No effect was observed when the same dose of tofogliflozin was administered intraperitoneally. ICV dapagliflozin and empagliflozin significantly enhanced food intake, although the strength of these effects varied among drugs. Food intake was most markedly enhanced when tofogliflozin was infused into the LV. Fewer or no effects were observed with infusion into the 3V or 4V, respectively. Systemic administration of liraglutide suppressed the effect of ICV tofogliflozin on food intake. ICV tofogliflozin increased phosphorylation of AMPK and c-fos expression in the lateral hypothalamus.ConclusionsSGLT2 inhibitors in the CNS increase food intake. SGLT2 activity in the CNS may regulate food intake through AMPK phosphorylation in the lateral hypothalamic area.
- Subjects :
- Lateral hypothalamus
Endocrinology, Diabetes and Metabolism
feeding behavior
030209 endocrinology & metabolism
AMP-Activated Protein Kinases
Pharmacology
Diseases of the endocrine glands. Clinical endocrinology
Eating
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Glucosides
Sodium-Glucose Transporter 2
Empagliflozin
Animals
Medicine
hypothalamus
Benzhydryl Compounds
Phosphorylation
Dapagliflozin
Sodium-Glucose Transporter 2 Inhibitors
facilitative
030304 developmental biology
0303 health sciences
business.industry
Liraglutide
Sodium
digestive, oral, and skin physiology
glucose transport proteins
AMPK
RC648-665
Adenosine Monophosphate
Rats
Metabolism
Glucose
Diabetes Mellitus, Type 2
chemistry
Hypothalamus
drug-related side effects and adverse reactions
Hypothalamic Area, Lateral
Systemic administration
Tofogliflozin
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20524897
- Volume :
- 9
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMJ Open Diabetes Research & Care
- Accession number :
- edsair.doi.dedup.....64b6d09a2930ca14be4b0734d3f00599